Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Latest Information Update: 21 Mar 2024
At a glance
- Drugs STP 705 (Primary)
- Indications Cholangiocarcinoma; Liver cancer; Liver metastases
- Focus Adverse reactions
- Sponsors Sirnaomics
Most Recent Events
- 15 Mar 2024 Status changed from active, no longer recruiting to completed.
- 28 Mar 2023 According to a Sirnaomics media release, first patient will be initiated into the study during second half of 2023.
- 13 Dec 2022 Status changed from recruiting to active, no longer recruiting.